What's Happening?
The U.S. Food and Drug Administration (FDA) has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer. This test, which will be commercialized by Abbott in the U.S., offers a new option for adults aged 45 and older who
are at average risk for colorectal cancer. The approval follows the PREEMPT CRC study, the largest clinical validation study for a blood-based colorectal cancer screening test, involving over 48,000 participants. SimpleScreen CRC detects cancer signals from cell-free DNA in the blood, providing a non-invasive alternative to traditional colonoscopy.
Why It's Important?
Colorectal cancer is a leading cause of cancer-related deaths in the U.S., yet many individuals remain unscreened due to the invasive nature of traditional methods. The approval of SimpleScreen CRC represents a significant advancement in cancer screening, potentially increasing participation rates by offering a less invasive option. This could lead to earlier detection and treatment, ultimately reducing mortality rates. The test's approval also aligns with Medicare coverage and American Cancer Society guidelines, enhancing accessibility for millions of Americans overdue for screening.
What's Next?
With FDA approval, Abbott plans to launch SimpleScreen CRC in the U.S. market, expanding its colorectal cancer screening portfolio. The test is expected to be integrated into healthcare practices, supported by Medicare coverage and potentially included in American Cancer Society guidelines. This development may prompt other companies to invest in similar non-invasive screening technologies, further transforming the landscape of cancer diagnostics. Additionally, Freenome aims to expand its portfolio with more blood-based tests for various cancers, leveraging its multiomics platform.
